CASC-IN: A New Tool to Diagnose Pre-Cachexia in Cancer Patients
Corresponding AuthorJosep M. Argilés
Cancer Research Group, Departament of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, Spain
A B S T R A C T
Purpose: The CASC-IN score has been designed with two very clear objectives: first, as a means to quantitatively assess pre-cachexia in cancer patients, and second, as a tool to discriminate the patients where cachexia staging is relevant. From this point of view, the CASC-IN tool is tightly linked with the so-called CAchexia SCOre (CASCO) previously described1 and validated2 by our research team. The results presented here classify a population of cancer patients into non-cachectic, precachectic or cachectic. Patients and Methods: An observational prospective case-control study has been performed and a total of 179 carcinoma patients and 117 age-matched control subjects were included. All the participants in the study were recruited at the Department of Medical Oncology (University of Cagliari, Cagliari, Italy) from June 2011 to September 2014. 179. Results: Using the mentioned patient's groups in the cancer group, --patients affected by a different tumour types-- the frequencies observed have been non-cachectic: 58 (32.4%), pre-cachectic: 7 (3.9%) and cachectic: 114 (63.7%). Conclusion: It is concluded that CASC-IN can be satisfactorily used for both assessing cachectic and precachectic cancer patients. It constitutes the only available tool for the classification of pre-cachectic patients.
Article TypeResearch Article
Publication historyReceived: Thu 10, Oct 2019
Accepted: Fri 15, Nov 2019
Published: Mon 30, Dec 2019
Copyright© 2023 Josep M. Argilés. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.